Theratechnologies Announces Commercialization Agreement for Tesamorelin in South Korea

Sep 01, 2015
PDF Version
Supporting Materials:

Theratechnologies Inc. (TSX:TH) is pleased to announce that it has concluded an agreement with BL&H Co., LTD (BL&H) for the distribution and commercialization of EGRIFTA™ (tesamorelin for injection) for the treatment of HIV-associated lipodystrophy in South Korea.